Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04883892
Other study ID # BMAC
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 15, 2021
Est. completion date July 2027

Study information

Verified date September 2023
Source Istituto Ortopedico Rizzoli
Contact Francesca Vannini, MD
Phone 051-6366878
Email francesca.vannini@ior.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the study is to compare the efficacy of the infiltrative therapy of BMAC vs HA up to 24 months in the treatment of the ankle osteoarthritis. The efficacy will be assessed through clinical, objective and subjective evaluations. After 12 months patients in the control group can decide to cross-over in the treatment group.


Description:

All the patients who meet the inclusion criteria and giving written informed consent will be randomized. We planned to enrol 120 patients. Following the randomization, every patient will be treated with a single injection of Bone Marrow Aspirate Concentrate (BMAC) or two injections of Hyaluronic Acid (HA) in the affected ankle. After the treatment patients will be followed up to 24 months whit clinical and radiological assessment. After 12 months patients in the control group can decide to cross-over in the treatment group with BMAC. These patients will be followed up further 12 months.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date July 2027
Est. primary completion date June 15, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Patients with degenerative ankle cartilage disease; 2. Unilateral involvement on the ankle; 3. Signs and symptoms of degenerative pathology of the ankle cartilage; 4. Radiographic or MRI signs of degenerative pathology of the ankle cartilage (OA Van Dijk grade 1-3); 5. No clinically significant electrocardiographic changes (recently performed ECG). 6. Ability and consent of patients to actively participate in clinical follow-up; Exclusion Criteria: 1. Patients unable to give consent; 2. Patients who have undergone intra-articular infiltration of another substance in the preceding 6 months; 3. Patients who have undergone ankle surgery in the preceding 12 months; 4. Patients with malignant neoplasms; 5. Patients with rheumatic diseases; 6. Patients with uncompensated diabetes; 9. Patients with uncompensated thyroid metabolic disorders; 10. Patients who abuse alcoholic beverages, drugs or medications; 11. Body Mass Index > 35;

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
BMAC
patients will be injected with BMAC into the ankle joint, after treatment patients will be followed up to 24 months. In particular patients will be assessed after treatment at 1, 3, 6, 12 and 24 months. During the injection, samples of BMAC will be collected for the characterization of the phenotype markers and clonogenic capability
HA
patients will be treated with two injection of HA, one every 15 days, into the ankle joint. After treatment these patients will be followed up to 24 months. At 12 months patients can decide to cross.over in the BMAC arm treatment. After cross-over patients will be assessed for further 12 months.

Locations

Country Name City State
Italy Istituto Ortopedico Rizzoli Bologna

Sponsors (1)

Lead Sponsor Collaborator
Istituto Ortopedico Rizzoli

Country where clinical trial is conducted

Italy, 

References & Publications (6)

Buda R, Vannini F, Castagnini F, Cavallo M, Ruffilli A, Ramponi L, Pagliazzi G, Giannini S. Regenerative treatment in osteochondral lesions of the talus: autologous chondrocyte implantation versus one-step bone marrow derived cells transplantation. Int Orthop. 2015 May;39(5):893-900. doi: 10.1007/s00264-015-2685-y. Epub 2015 Feb 8. — View Citation

Giannini S, Buda R, Cavallo M, Ruffilli A, Cenacchi A, Cavallo C, Vannini F. Cartilage repair evolution in post-traumatic osteochondral lesions of the talus: from open field autologous chondrocyte to bone-marrow-derived cells transplantation. Injury. 2010 Nov;41(11):1196-203. doi: 10.1016/j.injury.2010.09.028. Epub 2010 Oct 8. — View Citation

Kennedy JG, Murawski CD. The Treatment of Osteochondral Lesions of the Talus with Autologous Osteochondral Transplantation and Bone Marrow Aspirate Concentrate: Surgical Technique. Cartilage. 2011 Oct;2(4):327-36. doi: 10.1177/1947603511400726. — View Citation

Luciani D, Cadossi M, Tesei F, Chiarello E, Giannini S. Viscosupplementation for grade II osteoarthritis of the ankle: a prospective study at 18 months' follow-up. Chir Organi Mov. 2008 Dec;92(3):155-60. doi: 10.1007/s12306-008-0066-z. Epub 2008 Dec 6. — View Citation

Shapiro SA, Kazmerchak SE, Heckman MG, Zubair AC, O'Connor MI. A Prospective, Single-Blind, Placebo-Controlled Trial of Bone Marrow Aspirate Concentrate for Knee Osteoarthritis. Am J Sports Med. 2017 Jan;45(1):82-90. doi: 10.1177/0363546516662455. Epub 2016 Sep 30. — View Citation

Vannini F, Cavallo M, Ramponi L, Castagnini F, Massimi S, Giannini S, Buda RE. Return to Sports After Bone Marrow-Derived Cell Transplantation for Osteochondral Lesions of the Talus. Cartilage. 2017 Jan;8(1):80-87. doi: 10.1177/1947603516642574. Epub 2016 Apr 12. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other VAS function (Visual Analog Score - function) the scale is to expect the patient to select the number that best describes their functional disability status, in a range of length from 0 to 10 cm. The higher the value indicated the higher the degree of disability. Baseline, 1, 3, 6, 12, 24 months
Other VAS pain (Visual Analog Score - pain) the scale is to expect the patient to select the number that best describes their pain status, in a range of length from 0 to 10 cm. The higher the value indicated the higher the degree of disability. Baseline, 1, 3, 6, 12, 24 months
Other EuroQol Visual Analogue Scale (EQ-VAS) 0 - 100 scale where 100 is the "best possible health"and 0 is the "worst possible health" Baseline, 1, 3, 6, 12, 24 months
Other EQ-5D (EuroQoL) Current Health Assessment Score for the assessment of the quality of life of the patient. Baseline, 1, 3, 6, 12, 24 months
Other Patient Acceptable Symptom State (PASS) tool for assessing patient satisfaction in consideration of their current degree of pain, function and daily activity. The patient will evaluate his degree of satisfaction by answering a dichotomous closed question (yes / no). Baseline, 1, 3, 6, 12, 24 months
Other Evaluation of the osteoarthrosis progression of the ankle joint after treatment through radiological exams RX and MRI will be performed at 12 and 24 month after treatment 12, 24 months
Primary AOS (Ankle Osteoarthritis Scale) Evaluation of the change from baseline of the OAS score, assessing the trend of pain and function up to 24 months from the treatment Baseline, 1, 3, 6, 12, 24 months
Secondary AOFAS (The American Orthopedic Foot and Ankle Score) Score 0-100 made by 3 categories: Pain (0-40), Function (0-50) and Alignment (0-10).
The best clinical and function condition is represented by a score of 100. 0 is the worst possible condition.
Baseline, 1, 3, 6, 12, 24 months
See also
  Status Clinical Trial Phase
Completed NCT02508233 - Cross-cultural Adaptation and Validation of the Ankle Osteoarthritis Scale (AOS) for Use in French-speaking Populations N/A
Completed NCT01504438 - Prospective Randomized Evaluation of a Two and Three Piece Total Ankle Replacement N/A
Active, not recruiting NCT03440008 - Improving the Detection, Classification and Treatment of Misaligned Arthritic Ankles
Active, not recruiting NCT06404801 - Development of Stance Control Orthotic Knee Joint For Improvement of KAFO Users
Active, not recruiting NCT04405297 - A Disease-based Treatment Study for Diagnosed Osteoarthritis Utilizing Adipose-derived Regenerative Cells
Completed NCT01760577 - Effects of Intraarticular Botulinum Toxin A in Ankle Osteoarthritis N/A
Active, not recruiting NCT04998162 - Injections of SVF in Ankle Osteoarthritis N/A
Completed NCT03356951 - Gait Analysis Following Total Ankle Replacement and Subtalar Fusion N/A
Completed NCT02489188 - Gait Asymmetry Assessed Using Portable Gait Analysis System
Completed NCT01986244 - Total Ankle Replacement for Ankle Arthritis
Withdrawn NCT05562154 - Lateral Approach Versus Anterior Approach in Total Ankle Replacement N/A
Completed NCT03567187 - Cryoneurolysis for Improvements in Pain, ADL and QOL in Patients With Ankle Osteoarthritis N/A
Completed NCT05868759 - Assessment of Preoperative and Postoperative Ankle Kinematics N/A
Recruiting NCT06193057 - Comparison of Customized and Standard Total Ankle Prostheses N/A
Recruiting NCT06028763 - Development of Biomedical Technology for the Treatment of Ankle Cartilage Using Injectable Biocomposite Hydrogel N/A
Not yet recruiting NCT03573245 - Tranexamic Acid in Major Orthopedic Surgery: Comparison of 3 Dosage Regimen
Completed NCT04022928 - A Single Intraarticular Injection of Platelet-Rich Plasma on Pain and Physical Function in Patients With Ankle OA N/A
Completed NCT02629731 - Orthotic Dose Response Study N/A
Recruiting NCT03157141 - Ankle Osteoarthritis N/A
Active, not recruiting NCT03524729 - Do Rocker Bottom Shoes and Ankle-Foot Orthoses Reduce Pain and Improve Mobility for Ankle Osteoarthritis Patients N/A